Engineered fibroblast growth factor variants combined with engineered hepatocyte growth factor variants for treatment
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsJennifer R. COCHRAN, David Myung
Life of this patent
Estimating the term…
Abstract
The present invention provides polypeptide variants for use in treatment, in particular variants of fibroblast growth factor (FGF) and variants of hepatocyte growth factor (HGF) for use in combination to treat corneal epithelial defects (PCEDs) and/or corneal neovascularization.
Claims33
A method of treating and/or preventing persistent corneal epithelial defects (PCEDs) in a subject in need thereof, the method comprising administering an human hepatocyte growth factor (hHGF) variant and an human fibroblast growth factor 1 (FGF1) variant to the subject, thereby treating and/or preventing said PCED.
A method of treating, reducing, and/or preventing corneal neovascularization in a subject in need thereof, the method comprising administering an hHGF variant and an FGF variant to the subject, thereby treating, reducing, and/or preventing said corneal neovascularization.
Dependencies are inferred from the claim text.